Gilead Sciences CFO Sells Shares in Planned Transaction

Andrew Dickinson, the Chief Financial Officer of Gilead Sciences, Inc. (NasdaqGS: GILD), sold 3,000 shares of the company on June 15, 2026. The shares were sold at an average price of $125.4 each, amounting to a total transaction value of $376,200. This sale was part of a pre-arranged trading plan under Rule 10b5-1, indicating it was planned in advance.

Insider Buying and Selling at Gilead Sciences, Inc.

On June 15, 2026, Andrew Dickinson, the CFO, executed a planned sale of 3,000 shares. Johanna Mercier, Chief Communications and Corporate Affairs Officer, also sold 3,000 shares at an average price of $123.92 on the same day. Earlier, on June 10, Dickinson bought 2,796 shares, while Dietmar Berger, the Chief Medical Officer, sold 263 shares at $121.48. Daniel Patrick O'Day, the CEO, sold 8,779 shares on June 10 as well.

Other Institutional Activity in Gilead Sciences

Several major institutional investors have recently adjusted their positions in Gilead Sciences. BlackRock, Inc. trimmed its holdings by 4,184,605 shares, holding 119,010,973 shares worth about $16.59 billion. FMR LLC added 6,326,800 shares, bringing its total to 71,906,290 shares valued at approximately $10.02 billion. State Street Corp reduced its position by 381,933 shares, now holding 59,858,585 shares valued at $8.34 billion.

Gilead Sciences Stock Snapshot

Shares of Gilead Sciences, Inc. are trading around $124.3. The company has a market cap of about $154.3 billion and a P/E ratio of 16.91. Its 52-week range is between $104.46 and $157.29. The stock's 50-day moving average is $132.66, and its 200-day moving average is $129.21. Gilead's current ratio is 1.97, and it has a debt-to-equity ratio of 94.64.

Recent Earnings

Gilead Sciences reported revenues of $29.74 billion, reflecting a growth rate of 4.4%. The company achieved a net margin of 30.99% and a return on equity of 43.36%. Earnings per share stood at $7.35. The next earnings report is expected on August 6, 2026.

Dividend

Gilead Sciences offers an annual dividend rate of $3.28, yielding 2.64%. The payout ratio is 43.4%.

Analysts Set New Price Targets

On June 16, 2026, Cantor Fitzgerald reiterated its buy rating for Gilead Sciences with a price target of $155. Maxim Group upgraded the stock to a buy rating with a target of $165 on May 20. Truist Securities reiterated a buy rating with a target of $157 on May 8. The consensus recommendation for Gilead is a buy, with an average target price of $157.57 among 28 analysts.

About Gilead Sciences

Gilead Sciences, Inc. is a biopharmaceutical company based in Foster City, California. It focuses on discovering, developing, and commercializing medicines for unmet medical needs. The company's products include treatments for HIV, hepatitis, and COVID-19, among others. Led by CEO Daniel Patrick O'Day, Gilead employs approximately 17,000 people worldwide.

Bottom Line

Andrew Dickinson's planned sale of shares is a routine insider transaction, reflecting personal financial planning rather than a lack of confidence in Gilead Sciences. Investors closely watch such moves for insights into company leadership's view on stock valuation. Gilead remains a significant player in the healthcare sector, with analysts maintaining a positive outlook on its stock. As always, remember that insider transactions and analyst ratings are just pieces of the broader investment puzzle.